The therapy is also under development for SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Credit: PowerUp/Shutterstock. Mesoblast has gained US Food and Drug Administration
Vancouver, Canada, Dec. 24, 2024 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of
Antimicrobial resistance (AMR) is one of the top global public health and development threats. According to the World Health Organisation (WHO), an estimated 4.95 million